

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Victor ALDRICH et al.

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Rotary Blending Apparatus and System*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references listed on the attached form PTO-1449 as item nos. 21-26 are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☒ A copy of the International Search Report which issued on International Application No. PCT/US03/05680 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 1-3, 5-6, 9, 11, 13-14 and 19 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert J. Smith
Attorney of Record
Registration No. 40,820

Date: September 1, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9616
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4681USw		SERIAL NO. To be assigned			
				10/506346				APPLICANT Victor ALDRICH et al.	
								FILING DATE Concurrently herewith	
				U.S. PATENT DOCUMENTS					
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate		
	1.	1,955,929	04/24/1934	MUELLER					
	2.	2,014,032	09/10/1935	SHARPE et al.					
	3.	3,171,495	03/02/1965	PUCKETT					
	4.	4,627,432	12/09/1986	NEWELL et al.					
	5.	4,721,394	01/26/1988	CASTRO et al.					
	6.	4,722,608	02/02/1988	SALZMAN et al.					
	7.	4,778,054	10/18/1988	NEWELL et al.					
	8.	D299,066	12/20/1988	NEWELL et al.					
	9.	4,802,771	02/07/1989	WEETMAN					
	10.	4,811,731	03/14/1989	NEWELL et al.					
	11.	5,152,606	10/06/1992	BORRACCIA et al.					
	12.	D342,994	01/04/1994	RAND et al.					
	13.	5,326,168	07/05/1994	MIURA					
	14.	5,525,269	06/11/1996	CONNOLLY et al.					
	15.	5,590,654	01/07/1997	PRINCE					
	16.	5,837,630	11/17/1998	OWENS et al.					
	17.	5,860,419	01/19/1999	DAVIES et al.					
	18.	6,032,666	03/07/2000	DAVIES et al.					
	19.	6,334,705	01/01/2002	WEETMAN					
	20.	D468,009 S	12/31/2002	HOENDERKAMP et al.					
Continue on page _____									
FOREIGN PATENT DOCUMENTS									
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No		
	21.	GB 1561835	03/05/1980	GB					
	22.	GB2064336	06/17/1981	GB					
	23.	GB2129691	05/23/1984	GB					
	24.	WO 91/13646	09/19/1991	WIPO					
	25.	GB2246299	01/29/1992	GB					
Continue on page _____									
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
	26.	Gonda, "Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> 6(4):273-313 (1990).							
Continue on page _____									
EXAMINER					DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									